Andere Sprachen Eurocine Vaccines AB

Aktien

EUCI

SE0015382155

EUCI

Schlusskurs NORDIC GROWTH MARKET Andere Börsenplätze 00:00:00 21.05.2024			% 5 Tage	% 1. Jan.
0,0462 ^SEK	-7,60 %		+10,00 %	+0,43 %

28.02.	Eurocine Vaccines AB (publ) meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 31. Dezember 2023	CI
2023	Eurocine Vaccines AB (publ) meldet Ergebnis für das erste Quartal bis zum 30. September 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	28.02.
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024.	15.02.
Correction - Eurocine Vaccines discloses interim report for July - September 2023	28.11.
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2023	28.11.
Eurocine Vaccines discloses interim report for Juli - September 2023	28.11.
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	30.08.23
Eurocine Vaccines AB Reports Earnings Results for the Full Year Ended June 30, 2023	30.08.23
Eurocine Vaccines discloses interim report for July 2022 - March 2023	24.05.23
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	24.05.23
Eurocine Vaccines Wins SEK300,000 Grant from Merck KGaA	04.05.23
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 17-APR-2023.	17.04.23
Eurocine Vaccines discloses half-year report for July - December 2022	28.02.23
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	28.02.23
Eurocine Vaccines to Develop Chlamydia Vaccine Candidate Using mRNA	18.01.23
Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia	17.01.23
Eurocine Vaccines AB Decides to Develop mRNA-Based Vaccine Candidate Against Chlamydia	17.01.23
Outstanding results for Eurocine Vaccines' mRNA based HSV-2 candidate	21.12.22
Eurocine Vaccines : Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate	20.12.22
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2022	29.11.22
Eurocine Vaccines Receives Patent Coverage In South Korea For Vaccine Candidate	30.08.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Eurocine Vaccines AB

Aktien

EUCI

SE0015382155

EUCI

Andere Sprachen

Filter